Showing 461-470 of 8783 results for "".
How to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.Let’s Maximize Patient Interactions During Consultations
https://practicaldermatology.com/topics/practice-management/lets-maximize-patient-interactions-during-consultations/23892/To retain patients, be prepared to address these five common concerns.Strategies for Maximizing the Holiday Season: Planning for Profits in 2023
https://practicaldermatology.com/topics/practice-management/strategies-for-maximizing-the-holiday-season-planning-for-profits-in-2023/23835/How treatment and product packages can benefit you and your patients.DermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)Protect Your Practice from Fraud, Part 2
https://practicaldermatology.com/topics/practice-management/protect-your-practice-from-fraud-part-2/23606/Part 2 of this series reviews common in-office areas of your practice that may be susceptible to fraud and offers tips for protecting yourself and your practice.DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesMentorship Matters: Set the Pace for Long-term Success
https://practicaldermatology.com/topics/practice-management/mentorship-matters-set-the-pace-for-long-term-success/23406/Mentoring is one free strategy to building a better team. Here’s how a small but busy practice builds and develops its team and community through mentoring.Patients types that may be a great fit for ILUMYA™
https://practicaldermatology.com/topics/psoriasis/patients-types-that-may-be-a-great-fit-for-ilumya/19859/See how ILUMYA™ is a treatment option for a diverse range of patients with moderate-to-severe plaque psoriasis, including bio-naive and bio-experienced patients, and those aged 65 years or older.DERM2020 Content Recap: Kristine Kucera, PA-C
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-kristine-kucera-pa-c/19842/DERM2020 Faculty Kristine Kucera, PA-C covers her thoughts on the case presentations during DERM2020.Caring for Acne and Rosacea Patients in the COVID-19 Era
https://practicaldermatology.com/topics/acne-rosacea/caring-for-acne-and-rosacea-patients-in-the-covid-19-era/23280/Telederm may not be ideal, but it is essential for acne and rosacea patients today—and could persist in the future.